Article Page

Abstract

Recently, it is shown that there is a crucial contradiction within von Neumann’s theory [K. Nagata and T. Nakamura, Int. J. Theor. Phys. 49, 162 (2010)]. We derive a proposition concerning a quantum expected value under the assumption of the existence of the directions in a spin-1/2 system. The quantum predictions within the formalism of von Neumann’s projective measurement cannot coexist with the proposition concerning the existence of the directions. Therefore, we have to give up either the existence of the directions or the formalism of von Neumann’s projective measurement. Hence, there is a crucial contradiction within von Neumann’s theory. We discuss that this crucial contradiction makes the theoretical formulation of Deutsch’s algorithm questionable. Especially, we systematically describe our assertion based on more mathematical analysis using raw data. Our discussion, here, improves previously published argumentations very much whether Von Neumann’s Theory Meet al-Gly-Gly-Ala-Thr-Thr-Thr-Gly-Val-Thr peptide mimic modulators in α-synucleinopathy interfering amyloidogenesis Quantum Computated pathways.

Keywords

Von Neumann’s Theory; Meet; al-Gly-Gly-Ala-Thr-Thr-Thr-Gly-Val-Thr; peptide mimic; modulators; α-synucleinopathy; interfering amyloidogenesis; Quantum Computated; pathways; Quantum Measurement Theory, Quantum Computer, Formalism;Subject Areas; Applied Physics;

Article Type

Research Article - Abstract

Publication history

Received: Sep 20, 2017 Accepted: Sep 25, 2017 Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Can Von Neumann’s Theory Meet al-Gly-Gly-Ala-Thr-Thr-Thr-Gly-Val-Thr peptide mimic modulators in α-synucleinopathy interfering amyloidogenesis Quantum Computated pathways?

Authors Info

Grigoriadis Nikolaos Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM, Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece;

Grigoriadis Ioannis Department of Computer Drug Discovery Science, BiogenetoligandorolTM, Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece;

Grigoriadis George Department of Stem Cell Bank and ViroGeneaTM, Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece;

George Galazios Professor of Obstetrics and Gynecology, Democritus University of Thrace, Komotini, Greece;

E-mail: biogeneadrug@gmail.com